Merck & Co., Inc.
Merck & Co., Inc.
Your view on MRK
Overview
What the company does, where it operates, and who runs it.
About Merck & Co., Inc.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Robert M. Davis
- Headquarters
- 2000 Galloping Hill Road, Rahway, NJ, US
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Robert M. Davis
- Headquarters
- 2000 Galloping Hill Road, Rahway, NJ, US
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health.
The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.
It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers.
The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Merck & Co., Inc., and the rating behind it. MRK last traded at $145.45, 115.3× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Merck & Co., Inc.. Starting points for Merck & Co., Inc.: P/E 115.3, EPS $1.28, beta 0.22 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Merck & Co., Inc.. Merck & Co., Inc. paid $3.40 per share over the last year — a 2.3% yield at the current $145.45 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Merck & Co., Inc.. Trailing twelve-month EPS for Merck & Co., Inc. stands at $1.28. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Merck & Co., Inc.. Merck & Co., Inc. has reported as a listed company since 1978. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Merck & Co., Inc. valued side by side against its closest peers. Merck & Co., Inc. is measured against Drug Manufacturers - General peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Merck & Co., Inc., and how their positions are changing. At a $359.24B market value, institutional positions materially move Merck & Co., Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Merck & Co., Inc. executives and directors. Shares of Merck & Co., Inc. have traded between $73.31 and $105.07 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Merck & Co., Inc.. Merck & Co., Inc. is a $359.24B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Merck & Co., Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Merck & Co., Inc.. Coverage tracks Merck & Co., Inc. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.